口服补铁联合罗沙司他治疗尿毒症血液透析患者肾性贫血的效果及对不良反应的影响

目的探究口服补铁联合罗沙司他治疗尿毒症血液透析患者肾性贫血的效果及对不良反应的影响。方法选取本院2019年1月至2020年3月收治的尿毒症血液透析患者97例,根据随机分组法分为观察组(n=49)和对照组(n=48)。对照组口服补铁剂硫酸亚铁片治疗,观察组在对照组基础上加用罗沙司他胶囊治疗,比较两组血常规指标红细胞压积(Hct)、血红蛋白(Hb)、转铁蛋白饱和度(TSAT)、血清铁蛋白(SF)]及不良反应发生率。结果治疗前,两组Hb、Hct、SF、TSAT水平比较差异无统计学意义;治疗10周后,两组Hb、Hct、SF、TSAT水平均高于治疗前,且观察组高于照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论尿毒症血液透析患者口服补铁联合罗沙司治疗可改善肾性贫血病情,且安全性高,不良反应少。

Effect of oral iron supplementation combined with rosastat on renal anemia and adverse reactions in patients with uremia hemodialysis

Objective To explore effect of oral iron supplementation combined with rosastat on renal anemia and adverse reactions in patients with uremia hemodialysis. Methods 97 patients with hemodialysis who were admitted to our hospital from January 2019 to March 2020 were selected and they were divided into observation group(n=49) and control group(n=48) according to random grouping method. The control group took oral iron supplement ferrous sulfate tablets, and the observation group added roxastat capsules on the basis of the control group. The blood routine indexes hematocrit(Hct), hemoglobin(Hb), transferrin saturation(TSAT), serum ferritin(SF)] and the incidence of adverse reactions were compared between the two groups. Results Before treatment, there was no significant difference in the levels of Hb, Hct, SF, and TSAT between the two groups;after 10 weeks of treatment, the levels of Hb, Hct, SF, and TSAT in both groups were higher than those before treatment, and the observation group were higher than the control group, the difference was statistically significant(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups. Conclusion Oral iron supplementation combined with rosazone in hemodialysis patients with uremic disease can improve the condition of renal anemia, with high safety and few adverse reactions.